Adriamycin and CCNU in advanced breast cancer: A Southwest Oncology Group Study


    loading  Checking for direct PDF access through Ovid

Abstract

ADRIAMYCIN AND CCNU in identical combination and drug dosages as used by Einhorn et al, was evaluated in a groupwide study of advanced breast cancer. The overall response of 16% is far less than that reported previously and suggests that this combination cannot be recommended for extensive use.

    loading  Loading Related Articles